How Stringent Donor Criteria Can Shrink Blood Product Access

How Stringent Donor Criteria Can Shrink Blood Product Access
Download Whitepaper

Prepared by:

Zachry Vavra, Versiti Manager Quality Assurance; Olivier LaPuente, Versiti Professional Quality Assurance

Key highlights:

  • Stringent donor selection requirements drastically reduce the donor pool.
  • The compounded effects of donor select requirements reveal the critical need for careful consideration to balance precision with practical feasibility.

Executive Summary:

In biomedical research, stringent eligibility criteria for contributors of blood products and biospecimens are often necessary to ensure the precision and efficacy of studies. What often is not considered, however, is the impact of donor selection criteria on overall product availability.

By examining two specific case study examples, we gain insights into the challenges and implications of matching contributors to study requirements, highlighting the complexities and significant reductions in eligible donor pools.

Understanding the impacts of inclusion/exclusion criteria on donor pool eligibility can help you set more feasible criteria without compromising scientific rigor.

When seeking biospecimens for research purpose, it is important to consider donor eligibility criteria. These inclusion and exclusionary variables help to ensure precision, consistency, and efficacy of studies.

Defining Common Eligibility Criteria

Eligibility criteria for studies can vary significantly, however there are several common requirements shared by most studies. These requirements typically fall into basic categories: race, age, sex, body mass index (BMI), Human Leukocyte Antigen (HLA) type, and special infectious disease considerations such as Human Cytomegalovirus (CMV) status.

Race. Race-based criteria may involve the exclusion of a particular race, the inclusion of a single race, or a group of races.

Sex. When sex is specified, the requirement will always be for either females or males.

Age. Age requirements are usually expressed as a range or a specific age group.

BMI. Like age, BMI is specified as a range.

HLA Typing. Due to their crucial role in disease defense, HLA typing is a frequently requested criterion. It is often a group of alleles within a specific major or minor class or a single allele.

CMV Status. Often, studies require criteria that do not fall within the previously mentioned categories, such as CMV status.

In the case studies below, we will explore how enhanced eligibility criteria impact the potential donor pool.

Case Study 1

In this initial case, researchers aimed to identify a suitable donor who meets four specific criteria:

  • HLA-A2 positive
  • BMI between 25 and 30
  • Female
  • Age range of 25 to 44 years

Overlaying US-population data, we understand that HLA-A2 alleles are present in approximately 27.3% of the U.S. population. Within a repository of 2,000 recallable contributors, this would result in an initial pool of 546 potential donors. Considering that 35.1% of the U.S. population aged 25-44 has a BMI between 25 and 30, the eligible pool would further reduce to 192 individuals. Given that females constitute about half of the U.S. population, this pool would decrease to 97 potential donors. Additionally, since only 13.2% ofwomen in the U.S. fall within the 25 to 44 age range, the number of possible contributors would decline to 26.

Although the application of multiple eligibility criteria is a common practice, the combined effect of these requirements significantly narrows the pool of eligible contributors. In this case, the representative pool from a U.S. population-based bank is reduced by 98.7%, highlighting the substantial impact of stringent donor selection criteria (see Figure 1).

Stringent Donor Selection Figure 1

Case Study 2

The second case seeks to fulfill six distinct criteria. The donor must be:

  • White
  • Male
  • Age range of 18 to 35 years
  • CMV negative
  • HLA-A2:01 positive
  • BMI between 18 and 25

Within the U.S., 62.6% of the population identifies as white. For a donor bank with 8,000 recallable contributors, this demographic requirement equates to 5,008 individuals. Males ages 18 to 35 comprise 11.7% of the U.S. population, which further narrows the pool to 586 eligible contributors. The seroprevalence of CMV among white males ages 20 to 39 in the U.S. is approximately 28.7%, reducing the pool to 418 potential donors. The HLA-A2:01 allele is found in 29.6% of the white population, further decreasing the number of eligible contributors to 124 individuals. Finally, 34% of the white population has a BMI between 18 and 25, resulting in apool of just 42 eligible contributors.

The compounded effect of these specific criteria leads to a drastic reduction in the number of eligible donors. From an initial pool representative of the U.S. population, the pool is reduced by 99.5%, underscoring the significant impact of stringent donor selection criteria (see Figure 2).

Stringent Donor Criteria Figure 2

Having a partner that has an opt-in, recallable, diverse donor bank that spans geography helps to mitigate any homogenous demographics. It is critical to evaluate and prioritize donor criteria with your blood supplier before finalizing study protocols to ensure your study moves forward.

Summary

The detailed analysis of donor selection criteria underscores the significant challenges faced in blood banks for biomedical research. Through the case study examples, it becomes evident that stringent eligibility requirements drastically narrow the pool of potential donors.

For instance, the first case study’s criteria reduce the eligible contributors by 98.7%, while the second case study highlights a 99.5% reduction. The comprehensive overview of eligibility requirements further illustrates the multifaceted nature of donor selection, emphasizing race, sex, age, BMI, HLA typing, and CMV status as pivotal factors.

Ultimately, the compounded effects of these criteria reveal the critical need for careful consideration in donor requirements to balance precision with practical feasibility.

Consider the following:

  • Evaluate criteria early with your blood supplier.
  • Prioritize essential versus nice-to-have traits. Consider working with donor banks that can prescreen or enrich for specific attributes such as HLA typing, CMV status, etc.
  • Request a feasibility assessment before finalizing study protocols.
  • Identify a partner with a diverse donor pool, and potential geographic diversity if possible.

Donor precision is critical-but balancing it with supply feasibility ensures your study gets off the ground.

Appendix A

HLA Class I-A alleles frequency in US population by race and ethnicity

AEuropean FrequencyAfrican FrequencyAsian Pacific FrequencyHispanic Frequency
0101g17.18%4.74%5.08%6.70%
01020.01%0.65%0.00%0.30%
01030.01%0.02%0.00%0.00%
0116N0.01%0.00%0.00%0.00%
0201g29.60%12.46%9.46%19.40%
02020.08%4.20%0.03%0.68%
02030.00%0.02%3.16%0.03%
02040.00%0.02%0.00%0.28%
02050.80%1.87%0.34%1.48%
02060.20%0.02%4.83%3.92%
0207g0.00%0.00%4.38%0.00%
02100.00%0.00%0.09%0.00%
0211g0.00%0.02%1.16%0.33%
02120.00%0.00%0.00%0.03%
02130.01%0.02%0.00%0.08%
02140.00%0.02%0.00%0.00%
02160.00%0.00%0.11%0.00%
02170.05%0.00%0.00%0.35%
02190.01%0.00%0.00%0.00%
02200.01%0.02%0.06%0.15%
02220.00%0.02%0.00%0.20%
02240.02%0.00%0.00%0.00%
02300.02%0.00%0.00%0.03%
02420.00%0.00%0.03%0.00%
0253N0.00%0.00%0.03%0.00%
02600.00%0.06%0.00%0.03%
02740.00%0.02%0.00%0.00%
0301g14.35%8.13%2.60%7.91%
03020.28%0.08%0.54%0.18%
03050.01%0.00%0.00%0.00%
03070.00%0.00%0.00%0.00%
1101g5.64%1.58%17.90%4.62%
11020.18%0.00%1.53%0.00%
11030.01%0.00%0.03%0.00%
11040.03%0.00%0.00%0.03%
11050.01%0.00%0.00%0.00%
11190.00%0.00%0.03%0.00%
AEuropean FrequencyAfrican FrequencyAsian Pacific FrequencyHispanic Frequency
2301g1.68%10.77%0.23%3.69%
23050.00%0.02%0.00%0.03%
2402g8.69%2.21%18.24%12.32%
2403g0.11%0.04%0.57%0.20%
24050.00%0.00%0.00%0.05%
24070.01%0.08%1.78%0.05%
24080.00%0.00%0.06%0.00%
24100.00%0.00%0.25%0.00%
24140.00%0.00%0.00%0.03%
24170.00%0.04%0.42%0.00%
24200.00%0.00%0.17%0.00%
24220.00%0.00%0.00%0.13%
24250.00%0.00%0.00%0.25%
24260.01%0.00%0.00%0.08%
24580.01%0.00%0.00%0.00%
25011.93%0.50%0.06%0.88%
25020.01%0.00%0.00%0.00%
2601g2.95%1.41%3.90%2.89%
26020.00%0.00%0.73%0.03%
26030.00%0.02%0.14%0.00%
26070.00%0.00%0.00%0.03%
26080.04%0.04%0.00%0.10%
26090.01%0.00%0.00%0.00%
26120.00%0.04%0.00%0.00%
2901g0.22%0.10%1.44%0.35%
29023.28%3.64%0.14%4.17%
30011.34%6.91%2.06%2.11%
30020.92%6.22%0.06%2.81%
30040.07%0.21%0.34%0.25%
30100.00%0.00%0.00%0.15%
31012.35%1.04%3.25%4.79%
31020.01%0.00%0.00%0.15%
31040.00%0.02%0.00%0.00%
31090.00%0.00%0.00%0.03%
31120.00%0.00%0.03%0.00%
32013.13%1.41%1.30%2.71%
32060.00%0.00%0.00%0.03%
33010.99%2.12%0.11%1.96%
33030.13%4.45%9.43%1.31%
33050.03%0.00%0.00%0.00%
34010.00%0.04%1.58%0.03%
34020.04%3.35%0.03%0.33%

A

European Frequency

African Frequency

Asian Pacific Frequency

Hispanic Frequency

3403

0.00%

0.02%

0.00%

0.00%

3405

0.00%

0.00%

0.14%

0.00%

3601

0.01%

2.41%

0.00%

0.28%

3603

0.00%

0.02%

0.00%

0.00%

4301

0.00%

0.02%

0.00%

0.00%

6601

0.26%

1.48%

0.03%

0.55%

6602

0.00%

0.79%

0.00%

0.10%

6603

0.00%

0.23%

0.00%

0.00%

6801g

2.50%

3.68%

1.86%

4.69%

6802

0.85%

6.51%

0.03%

2.46%

6803

0.01%

0.00%

0.03%

1.38%

6805

0.00%

0.02%

0.00%

0.35%

6807

0.00%

0.00%

0.00%

0.03%

6815

0.00%

0.02%

0.00%

0.00%

6825

0.01%

0.00%

0.00%

0.00%

6901

0.08%

0.04%

0.14%

0.55%

7401g

0.01%

5.22%

0.11%

0.75%

7403

0.02%

0.02%

0.00%

0.00%

7409

0.00%

0.06%

0.00%

0.00%

7411

0.00%

0.06%

0.00%

0.00%

8001

0.00%

0.71%

0.00%

0.25%

Source: Maiers, M., Gragert, L., Klitz, W. High resolution HLA alleles and haplotypes in the US population. Human Immunology (2007) 68, 779-788.

https://pubmed.ncbi.nlm.nih.gov/17869653/

Appendix B

US population by age and sex

 


TotalPercentMalePercent MaleFemalePercent Female
Total population333,287,562100.0%165,228,21449.6%168,059,34850.4%
Under 5 years18,358,1995.50%9,394,8905.70%8,963,3095.30%
5 to 9 years19,770,3145.90%10,110,9176.10%9,659,3975.70%
10 to 14 years21,220,2146.40%10,892,4156.60%10,327,7996.10%
15 to 19 years21,785,6586.50%11,167,5226.80%10,618,1366.30%
20 to 24 years22,446,0406.70%11,488,5777.00%10,957,4636.50%
25 to 29 years22,007,6286.60%11,245,2606.80%10,762,3686.40%
30 to 34 years23,225,6367.00%11,785,0907.10%11,440,5466.80%
35 to 39 years22,335,8596.70%11,322,5226.90%11,013,3376.60%

 


TotalPercentMalePercent MaleFemalePercent Female
40 to 44 years21,711,7856.50%10,939,8436.60%10,771,9426.40%
45 to 49 years19,640,9255.90%9,853,1986.00%9,787,7275.80%
50 to 54 years20,835,5216.30%10,447,3946.30%10,388,1276.20%
55 to 59 years20,553,6156.20%10,163,4546.20%10,390,1616.20%
60 to 64 years21,573,8536.50%10,492,4886.40%11,081,3656.60%
65 to 69 years18,559,4975.60%8,798,9685.30%9,760,5295.80%
70 to 74 years15,338,5754.60%7,149,8504.30%8,188,7254.90%
75 to 79 years11,005,4613.30%4,901,5873.00%6,103,8743.60%
80 to 84 years6,758,8392.00%2,861,1521.70%3,897,6872.30%
85 years and over6,159,9431.80%2,213,0871.30%3,946,8562.30%

US population by selected age categories

 


TotalPercentMalePercent MaleFemalePercent Female
5 to 14 years40,990,52812.321,003,33212.719,987,19611.9
15 to 17 years12,976,8753.96,655,45546,321,4203.8
Under 18 years72,325,60221.737,053,67722.435,271,92521
18 to 24 years31,254,8239.416,000,6449.715,254,1799.1
15 to 44 years133,512,60640.167,948,81441.165,563,79239
16 years and over269,555,31880.9132,607,01680.3136,948,30281.5
18 years and over260,961,96078.3128,174,53777.6132,787,42379
21 years and over247,659,64974.3121,344,24173.4126,315,40875.2
60 years and over79,396,16823.836,417,1322242,979,03625.6
62 years and over70,685,24721.232,135,42219.438,549,82522.9
65 years and over57,822,31517.325,924,64415.731,897,67119
75 years and over23,924,2437.29,975,826613,948,4178.3

Source: US Census 2022 American Community Survey 1-Year Estimates

Appendix C

US population by race

Total:

331,449,281



Population of one race:

297,600,338

89.79%

White alone

204,277,273

61.63%

Black or African American alone

41,1042,00

12.40%

American Indian and Alaska Native alone

3,727,135

1.12%

Asian alone

19,886,049

6.00%

Native Hawaiian and Other Pacific Islander alone

689,966

0.21%

Source: US Census 2022 American Community Survey 1-Year Estimates

Appendix D

Body Mass Index (BMI) by age

AgeBMI is less than 18BMI is greater than or equal to 18 and less than 25BMI is greater than or equal to 25 and less than 30BMI is greater than or equal to 30 and less than 40BMI is 40 or greater
Ages 20-243.10%52.20%26.10%15.30%3.40%
Ages 25-441.40%34.40%35.10%24.60%4.50%
Ages 45-640.70%28.00%37.60%28.50%5.30%
Age 65 and older2.20%31.10%39.00%24.40%3.40%

Source: Center for Financing, Access, and Cost Trends, AHRQ, Household and Pharmacy Components of the Medical Expenditure Panel Survey, 2009

Appendix E

Cytomegalovirus Seroprevalence in the US

Age, Total YearsSample SizeAge-adjusted Prevalence Estimate
Categories22,63958.9%
6-112,67936.3%
12-192,91841.7%
20-293,30249.3%
30-393,15654.2%
40-492,48364.5%
50-591,80074.2%
60-692,25783%
70-791,72188.8%
>801,32390.8%
Sex



Male10,24354.1%
Female11,39663.5%
Race/Ethnicity



Non-Hispanic white8,21251.2%
Non-Hispanic Black6,22875.8%
Mexican American6,29681.7%

Source: https://doi.org/10.1086/508173
https://academic.oup.com/cid/issue/43/9
Clinical Infectious Diseases, Volume 43, Issue 9, 1 November 2006, Pages 1143–1151
Seroprevalence of Cytomegalovirus Infection in the United States, 1988–1994
Stephanie A. S. Staras, Sheila C. Dollard, Kay W. Radford,
W. Dana Flanders, Robert F. Pass, Michael J. Cannon

 
Clinical Trial Management
Versiti Clinical Trial Services provides end-to-end trial management services for the successful execution of clinical studies.
 
Diagnostic, Analytical, Laboratory, & Research Services
Versiti Clinical Trial Services provides central laboratory services, including sample testing, assay development, site management and more.
 
Quality & Regulatory Services
Versiti’s Quality and Regulatory services equip therapeutic developers with the expertise to navigate complex regulations and ensure compliance.